Oelschlager Kristen M

COO Oelschlager sells 14,888 shares of CSTL at $39.31; retains 12,323 post-sale. Stock up 13.8% in 30d, 61.6% in 90d.

Oelschlager Kristen M, Chief Operating Officer of Castle Biosciences, sold 14,888 shares at $39.31 on 2025-12-17, reducing her holdings by 54.7% from 27,211 to 12,323 shares. The sale occurred when the stock was trading -1.3% from its 52-week high of $39.95, near a recent peak. Castle Biosciences has shown strong 30-day (+13.8%) and 90-day (+61.6%) price appreciation, and the company reports 51.1% annual revenue growth on $83.0M quarterly revenue, despite a -$501.0K net loss. The timing of this substantial reduction in executive holdings, at near-peak valuations and following sustained momentum, warrants monitoring of the company's forward guidance and operational trajectory.

COO Oelschlager sells 18,932 shares of CSTL for $664.5K, reducing holdings by 60.6% on day stock trades 52.6% above 30-day average.

Oelschlager Kristen M, Chief Operating Officer, sold 18,932 shares at $35.10 on 2025-11-11, reducing her stake from 31,255 to 12,323 shares—a 60.6% reduction in holdings. The sale occurred while CSTL traded near its 52-week high of $34.97, with the stock up 52.6% over the prior 30 days and 69.8% over 90 days, suggesting the sale captured significant recent momentum. The company shows strong annual revenue growth of 51.1% to $83.0M but is unprofitable (net income of $-501.0K in the latest quarter), trading at a P/E of 51.70 with a market cap of $995.9M—valuation metrics that may reflect the market's growth expectations rather than current earnings power. The substantial sale, executed at a favorable price point after an extended rally, warrants examination of whether execution or strategic positioning drove the decision.